Shionogi & Co., Ltd.
Notice of Basic Policy Decision on the Absorption-Type Merger of Our Wholly Owned Subsidiary Torii Pharmaceutical Co., Ltd.
Shionogi & Co., Ltd. has decided on the basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. through a merger effective April 1, 2027.
Key Figures
- Merger Effective Date: Scheduled April 1, 2027
- Shionogi & Co., Ltd. Consolidated Revenue: 438,268 million JPY (Fiscal Year Ending March 2025)
- Torii Pharmaceutical Standalone Net Sales: 60,426 million JPY (Fiscal Year Ending December 2024)
AI要約
Overview of the M&A
Shionogi & Co., Ltd. resolved at the Board of Directors meeting on February 20, 2026, the basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. through an absorption-type merger effective April 1, 2027. Torii Pharmaceutical became a wholly owned subsidiary on September 1, 2025, and this merger aims to strengthen collaboration between the two companies and maximize integration synergies. The merger will be conducted as an absorption-type merger, with Torii Pharmaceutical as the dissolved company, and there will be no issuance of new shares or allocation of cash.
Future Outlook and Impact
As this merger is between a parent company and its wholly owned subsidiary, the impact on Shionogi & Co., Ltd.'s consolidated performance is expected to be minimal. Detailed schedules concerning the merger will be disclosed as soon as they are decided. After the merger, there will be no changes to the trade name, location, representatives, business content, capital stock, or fiscal year-end.
